Causal mechanisms of aging
Knowing which molecular changes actually cause age-related decline, and having a validated measure of biological age that responds to intervention.
State of the art
Partial reprogramming restored visual function in aged and injured mouse and macaque retina (2020-2024); FDA has qualified no epigenetic clock as a surrogate endpoint, so human aging trials still need disease endpoints.
- No validated surrogate biomarker of biological age, so any whole-body rejuvenation claim needs decade-long outcome trials
- Hallmarks of aging are correlated; interventions cannot yet be attributed to a specific causal node
- Mouse lifespan results have repeatedly failed to transfer to longer-lived species
Who’s working on it
- Life Biosciences ↗Startup
Partial epigenetic reprogramming (OSK); started the first human trial of ER-100 in optic neuropathies in Q1 2026 and raised an $80M Series D in April 2026
- Retro Biosciences ↗Startup
Dosed its first clinical candidate RTR242 in 2025 and raised a round at a $1.8B pre-money valuation in 2026, across cell therapy, reprogramming and protein design
- Altos LabsStartup
Launched in 2022 with roughly $3B to pursue cellular rejuvenation programming, the largest private bet on reprogramming-based aging biology
- Steve HorvathResearcherAltos Labs
Built the epigenetic clocks (2013 onward) that are the leading candidate biological-age measures; moved from UCLA to Altos Labs in 2022
- Hevolution Foundation ↗Program
Non-profit launched in 2021 in Riyadh that funds healthspan-biology grants and early-stage companies worldwide, the largest dedicated funder outside the NIH
- NIA Interventions Testing ProgramProgram
Runs blinded multi-site mouse lifespan trials that independently replicate candidate interventions, the field's main defence against non-reproducible results
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Interventional nonhuman-primate cohorts with deep longitudinal multi-omic and functional phenotyping, long enough to test whether clocks track outcomes | $$$ $100M – $1B |
| policy | Biomarker qualification program so a measurable intermediate endpoint can support aging indications | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.